1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A

Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A

SSZSE:002864
20.40
CNY
+0.52
(+2.62%)
2.74BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.68
2.92
3.05
3.63
4.31
4.37
5.43
6
7.99
8.74
7.86
7.16
8.39
- -
Basic EPS, GAAP
0.39
0.48
0.51
0.47
0.5
0.58
0.64
0.71
0.84
0.91
0.88
0.88
0.71
- -
Free Cash Flow per Basic Share
- -
0.19
-0.05
0.53
0.06
0.24
0.31
0.19
0.32
0.62
0.33
0.55
0.15
- -
Dividend per Share
0.02
0.02
0.02
0.02
- -
0.08
0.08
0.15
0.16
0.19
0.19
0.18
0.32
0.01
Book Value per Share
2.5
2.91
3.41
3.88
4.93
5.43
5.99
6.4
7.02
8.25
11.21
11.84
12.21
12.56
Tangible Book Value per Share
2.36
2.51
2.65
3.12
4.38
4.89
5.46
5.88
6.52
7.76
10.83
11.46
11.83
12.17
Basic Weighted Avg Shares
85
84
84
84
87
112
112
112
111
111
125
136
136
136
Sales/Revenue/Turnover
227
246
256
305
377
489
611
670
887
974
981
974
1,141
- -
Operating Margin (%)
15.58
19.31
19.2
14.67
13.2
11.58
13.3
14.11
12.4
12.8
12.78
12
10.72
- -
Depreciation Expense
- -
6
8
8
11
12
13
14
17
18
31
33
37
- -
Net Income, GAAP
33
40
43
40
44
65
72
79
93
101
110
120
96
- -
Effective Tax Rate (%)
13.91
14.53
13.8
14.29
12.59
14.12
14.09
14.19
13.27
13.45
13.7
12.43
11.87
- -
Profit Margin (%)
14.52
16.31
16.65
12.94
11.6
13.22
11.75
11.8
10.5
10.38
11.26
12.35
8.44
- -
Working Capital
98
110
116
151
363
411
456
517
519
579
1,197
1,325
1,279
1,329
LT Debt
- -
- -
- -
- -
- -
- -
- -
57
42
28
2
101
2
3
Total Equity
211
246
289
328
556
612
675
736
807
948
1,551
1,637
1,689
1,737
Return on Invested Capital (%)
- -
13.84
13.69
11.32
9.53
9.62
11.42
10.96
11.31
9.43
7.8
7.08
5.49
- -
Return on Capital (%)
- -
16.95
14.71
12.37
9.75
11.08
11.16
10.76
11.04
9.86
7.65
7.09
5.5
- -
Return on Common Equity (%)
- -
17.53
15.97
12.83
9.9
11.08
11.16
11.34
12.32
11.76
8.91
7.55
5.8
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
99
51
51
LT Borrowings
- -
100
1
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
138
138
138
Market Capitalization
3,278
3,549
2,742

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,803
1,918
1,828
Cash, Cash Equivalents & STI
1,095
1,230
1,197
Accounts Receivable, Net
423
417
373
Inventories
111
117
110
Total Current Liabilities
524
510
499
Payables & Accruals
- -
- -
- -
ST Debt
99
51
51
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.19%
19.91%
3.17%
Free Cash Flow
-64.05%
26.28%
-72.36%
Net Income, GAAP
9.69%
4.89%
-19.95%
Sales/Revenue/Turnover
16.63%
11.86%
17.15%
Total Cash Common Dividend
- -
24.26%
79.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
210
245
262
257
974
2025
250
324
- -
299
1,141
2026
223
200
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.21
0.22
0.23
0.88
2025
0.23
0.21
- -
0.05
0.71
2026
0.16
0.15
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.18
0.01
-0.01
0.18
2025
0.04
0.2
- -
- -
0.32
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xiao Lin Xie
Full Time Employees
926
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 2801, Baliu 2nd Road Xi'an SA China 710025
IPO Date
Nov 16, 2017
Website
pljt.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd is a high-tech enterprise in China specializing in the comprehensive integration of pharmaceutical activities. The company's operations encompass the research and development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products, alongside the cultivation of medicinal raw materials under Good Agricultural Practices (GAP) standards. They focus on delivering Chinese patent medicines and a broad spectrum of drugs addressing various therapeutic areas, including pain relief, cardiovascular health, digestive issues, respiratory conditions, and treatments for pediatric and gynecological ailments. The company also offers products for hepatobiliary, rheumatism and bone injury, and general tonic categories, as well as heat-clearing and detoxifying agents and traditional Chinese medicine anti-inflammatory solutions. Recent developments include obtaining approval for clinical trials on an osteoarthritis plaster and a knee osteoarthritis gel patch, and marketing approval for a new pain relief gel. Founded in 1997, the company maintains its headquarters in Xi'an, China.